Evidence map›Paper›PMID 41331085›Full record

ArticleNPJ precision oncology2025

Characterizing circulating rare cells in peripheral blood for detecting and monitoring multiple myeloma and precursor states.

Stephanie N Shishido, Jeremy Mason, Mohamed Kamal, Sonia Maryam Setayesh, Amishi U Vora, David Berrios, Luz Yurany Moreno Rueda, Krina Patel, Elisabet E Manasanch, Robert Z Orlowski and 1 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Stephanie N ShishidoConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, USA.
Jeremy MasonConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, USA.
Mohamed KamalConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, USA.
Sonia Maryam SetayeshConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, USA.
Amishi U VoraDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
David BerriosDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Luz Yurany Moreno RuedaDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Krina PatelDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elisabet E ManasanchDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Robert Z OrlowskiDepartment of Lymphoma and Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Peter KuhnConvergent Science Institute for Cancer, Michelson Center, University of Southern California, Los Angeles, CA, USA. PKuhn@usc.edu.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Multi-modal Liquid Biopsy Early Assessment of Breast Cancer, Pancreatic Cancer, and Multiple MyelomaU01CA285013 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KUHN, PETER · 2023 to 2025
$3.4M
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation R-202312-00614NCI NIH HHS P30 CA014089NCI NIH HHS U01 CA285013NCI NIH HHS U01CA285013USC Norris Comprehensive Cancer Center 5P30CA014089-40
6 · The paper itself

Abstract

Multiple myeloma (MM) arises from abnormal plasma cells (PCs) progressing from precursor states, including monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Understanding this transition and progression to overt MM requires improved non-invasive strategies. We employed a liquid biopsy approach to detect and characterize circulating PCs across disease states in 68 patients (MGUS = 11, SMM = 21, NDMM = 19, RRMM = 17) using multi-channel immunofluorescence staining and machine learning-assisted rare event detection. PCs were identified by CD138 and B-cell maturation antigen (BCMA) expressions, with distinct phenotypic subpopulations stratifying disease states. The D | CD138 | BCMA-Memb phenotype was the most predictive, with incidence increasing from MGUS to SMM and overt MM (p < 0.005). Multivariate modeling distinguished precursors from overt disease with 86% accuracy. Shifts in BCMA and CD45 expression suggested immune cell profile alterations with progression and treatment. These findings underscore PB-based liquid biopsy as a promising tool for MM detection and monitoring, revealing circulating PC heterogeneity.

Identifiers

PMID41331085
PMCPMC12672686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.